Elevated lipoprotein(a) (Lp[a]) is an independent, genetic risk factor for atherosclerotic cardiovascular disease (ASCVD) that impacts ~1.4 billion people globally. Generally, Lp(a) levels remain stable over time; thus, most individuals need only undergo Lp(a) testing through a non-fasting blood draw once in their lifetime, unless elevated Lp(a) is identified. Despite the convenience of the test for clinicians and patients, routine Lp(a) testing has not been widely adopted. This review provides a guide to the benefits of Lp(a) testing and solutions for overcoming common barriers in practice, including access to testing and lack of awareness. Lp(a) testing provides the opportunity to reclassify ASCVD risk and drive intensive cardiovascular risk factor management in individuals with elevated Lp(a), and to identify patients potentially less likely to respond to statins. Moreover, cascade screening can help to identify elevated Lp(a) in relatives of individuals with a personal or family history of premature ASCVD. Overall, given the profound impact of elevated Lp(a) on cardiovascular risk, Lp(a) testing should be an essential component of risk assessment by primary and specialty care providers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10945898 | PMC |
| http://dx.doi.org/10.1016/j.ahjo.2023.100350 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Increasing provider awareness of Lp(a) testing for patients at risk for cardiovascular disease: A comparative study.
Am J Prev Cardiol
March 2025
St. Elizabeth Healthcare, 20 Medical Village Drive, Suite 103, Edgewood, KY 41017, USA.
Background: Lipoprotein(a) [Lp(a)] is a low-density lipoprotein variant with atherogenic, thrombogenic, and pro-inflammatory properties that may have numerous pathologic effects, including dyslipidemia. Screening for Lp(a) is clinically significant, due to its causal role in atherosclerotic cardiovascular disease (ASCVD). Among clinicians, however, there remains a general lack of both clinical awareness of Lp(a) and adequate tools to track Lp(a) testing in patients.
View Article and Find Full Text PDFMore absolute moderate-to-vigorous physical activity is associated with better health-related quality of life in outpatients with an acquired brain injury.
Front Rehabil Sci
December 2024
Department of Medicine, Université de Sherbrooke, Sherbrooke, QC, Canada.
Health-related quality of life (HRQoL) is a patient-perceived measure of physical, social, and emotional health. Acquired brain injury (ABI) occurs due to damage to the brain after birth. Individuals with an ABI typically present with reduced HRQoL and require additional support to maintain their HRQoL.
View Article and Find Full Text PDFUnveiling the Synergy of Serum Lipoprotein-Associated Phospholipase A2 and PLA2G7 Gene Polymorphism (rs1805017) as Key Determinants of Coronary Artery Disease Risk and Severity: Implications for Early Intervention.
Cureus
November 2024
Biochemistry, Nizam's Institute of Medical Sciences, Hyderabad, IND.
Background Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a key enzyme selectively expressed in unstable, rupture-prone atherosclerotic plaques. Previous research has established a strong link between the gene and the development of coronary artery disease (CAD). While traditional risk factors like cholesterol levels and blood pressure are valuable, there remains a need for more specific biomarkers to identify individuals at heightened risk of atherosclerosis before the onset of clinical symptoms.
View Article and Find Full Text PDFNew cardiovascular disease markers in patients with familial hypercholesterolemia carriers of genetic variants.
J Diabetes Metab Disord
June 2025
Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, Minas Gerias Brazil.
Objectives: Familial hypercholesterolemia (FH) is an autosomal dominant genetic disease characterized by elevated levels of low-density lipoprotein cholesterol (LDLc). The early diagnosis of FH can reduce unfavorable outcomes in this population, but genetic study is not available in all populations. This study aimed to evaluate new cardiovascular plasma markers (GDF-15, CXCL16, FABP3, FABP4, LIGHT, sCD14, ucMGP), as well as Lp(a) levels, in individuals genetically characterized for FH, classified according to treatment with statins.
View Article and Find Full Text PDFPrimary Hypoalphalipoproteinemia With Significant Premature Atherosclerosis.
JACC Case Rep
December 2024
Cardiology Division, Department of Medicine, Stony Brook University Hospital, Stony Brook, New York, USA.
Primary hypoalphalipoproteinemia is typically caused by genetic disorders and is characterized by low high-density-lipoprotein cholesterol (HDL-C). Low HDL-C has been proposed to confer an increased risk of atherosclerotic cardiovascular disease; however, a causal relationship has not been determined. We describe the case of an otherwise healthy and asymptomatic 37-year-old woman with severely low HDL-C who was found to have significant coronary artery disease in whom genetic testing supported a diagnosis of Tangier disease.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!